drugset / Trial / NCT00238784

SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

NCT00238784 ↗

Phase 3 Completed 1300 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma

Timeline

Start
2004-05
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled

Indications